

ALLIA.143C1



PATENT

#14  
Jm  
1/11/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Zaghouani, H. ) Group Art Unit 1644  
Appl. No. : 09/623,728 )  
Filed : January 22, 2001 )  
For : Compounds, Compositions and )  
Methods for the Endocytic )  
Presentation of Immunosuppressive )  
Factors )  
Examiner : P. Nolan )

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on

December 24, 2002  
Christine Hughey  
Christine Hughey

RECEIVED

JAN 06 2003

AMENDMENT AND RESPONSE TO OFFICE ACTION

TECH CENTER 1600/2900

United States Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202

Dear Sir:

In response to the Office Action dated June 25, 2002, applicant submits the following response:

Remarks

Claims 1 - 7 and 21 - 28 are pending in the application.

Rejection of the Claims under 35 USC 112(1)

Claims 1 - 7 and 21 - 28 are rejected under 35 USC 112(1) as containing subject matter not described in the specification. The Office Action states that there is no support for the phrase "is derived from a protein responsible for an autoimmune disease" as recited in claim 1. However, applicant respectfully disagrees. On page 8, lines 19 - 22 of WO 00/001732 (PCT Publication from which this application is a U.S. national application), states:

Accordingly, efficient FcR mediated presentation of appropriate TCR antagonists or agonists (wherein the agonists may be derived from autoantigenic polypeptides or